Compare Incyte Corporation (INCY) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.66 (market cap $7.77B). The key difference: Incyte Corporation is far larger — about 2.9× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| INCY | PDBC | |
|---|---|---|
Market Cap | $22.85B | $7.77B |
Volume | 1,927,029 | 6,100,303 |
Sector | Health | — |
52-Week High | $129.93 | $20.10 |
52-Week Low | $83.80 | $13.16 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $19.65, up 1.24% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The ETF has delivered strong performance, rising 45.66% year-to-date as of Q3 2026, driven by energy and agricultural commodity gains amid geopolitical tensions. Recent institutional interest includes new positions from Arlington Capital Management and Advisortrust Partners, though short interest surged 215.4% in September 2026, indicating mixed sentiment.
The outlook for PDBC remains positive due to robust commodity trends and defensive investor shifts, but risks include heightened short interest and geopolitical volatility. Further upside depends on sustained commodity strength, while a pullback could test support near $19.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
